4th Quarter - Report

MCDERMOTT+ LLC for CAMPAIGN FOR SUSTAINABLE DRUG PRICING

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Prescription drug pricing H.R. 2113 - Prescription Drug STAR Act S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 1865 - Further Consolidated Appropriations Act, 2020

LobbyistCovered position, as disclosed
RODNEY WHITLOCK 2011-2015: Health Policy Director, Sen. Chuck Grassley; 2005-2010: Health Policy Advisor, Senate Finance Committee; 2003-2005: Legislative Director, Rep. Charlie Norwood; 1997-2002: Legislative Assistant, Rep. Charlie Norwood

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2113 (116th), S. 2543 (116th), H.R. 1865 (116th), S. 551 (116th), H.R. 3 (116th)

Health Issues HCR

Prescription drug pricing S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 340 and H.R. 965 - CREATES Act S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R. 2113 - Prescription Drug STAR Act S. 617 - Second Look at Drug Patents Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 1865 - Further Consolidated Appropriations Act, 2020 USMCA

LobbyistCovered position, as disclosed
RODNEY WHITLOCK 2011-2015: Health Policy Director, Sen. Chuck Grassley; 2005-2010: Health Policy Advisor, Senate Finance Committee; 2003-2005: Legislative Director, Rep. Charlie Norwood; 1997-2002: Legislative Assistant, Rep. Charlie Norwood

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2374 (116th), S. 2543 (116th), H.R. 1865 (116th), S. 340 (116th), S. 440 (116th), S. 1391 (116th), H.R. 1503 (116th), S. 551 (116th), S. 1209 (116th), H.R. 2296 (116th), S. 1224 (116th), S. 659 (116th), S. 617 (116th), H.R. 1520 (116th), H.R. 2113 (116th), S. 1416 (116th), S. 1895 (116th), H.R. 3 (116th), H.R. 965 (116th)

Trade (domestic/foreign) TRD

USMCA

LobbyistCovered position, as disclosed
RODNEY WHITLOCK 2011-2015: Health Policy Director, Sen. Chuck Grassley; 2005-2010: Health Policy Advisor, Senate Finance Committee; 2003-2005: Legislative Director, Rep. Charlie Norwood; 1997-2002: Legislative Assistant, Rep. Charlie Norwood

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Pharmacy PHA

Prescription drug pricing S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 340 and H.R. 965 - CREATES Act S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R. 2113 - Prescription Drug STAR Act H.R. 985 - FAST Generics Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019

LobbyistCovered position, as disclosed
RODNEY WHITLOCK 2011-2015: Health Policy Director, Sen. Chuck Grassley; 2005-2010: Health Policy Advisor, Senate Finance Committee; 2003-2005: Legislative Director, Rep. Charlie Norwood; 1997-2002: Legislative Assistant, Rep. Charlie Norwood

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 2113 (116th), S. 1416 (116th), H.R. 3 (116th), S. 440 (116th), S. 340 (116th), H.R. 965 (116th), S. 659 (116th), S. 1895 (116th), H.R. 2374 (116th), H.R. 1503 (116th), H.R. 2296 (116th), S. 2543 (116th), S. 1391 (116th), S. 1209 (116th), S. 551 (116th), S. 1224 (116th), H.R. 1520 (116th), H.R. 985 (116th)

Copyright/Patent/Trademark CPT

Patent abuse S. 440 - PACED Act H.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S. 617 - Second Look at Drug Patents Act of 2019 S. 1416 - The Affordable Prescriptions for Patients Act S. 1224 - The Stop STALLING Act

LobbyistCovered position, as disclosed
RODNEY WHITLOCK 2011-2015: Health Policy Director, Sen. Chuck Grassley; 2005-2010: Health Policy Advisor, Senate Finance Committee; 2003-2005: Legislative Director, Rep. Charlie Norwood; 1997-2002: Legislative Assistant, Rep. Charlie Norwood

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2375 (116th), H.R. 1499 (116th), S. 1416 (116th), S. 617 (116th), S. 440 (116th), S. 1224 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.